Payment overview · 2025
General Payments
$329.75
16 reported records · 5 companies
Healthcare provider profile · identity verified
Randall Perry Scott, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLAGSTAFF, AZ · NPI 1235138744
Verified facts
What the public records show
CMS Open Payments records show Randall Perry Scott, MD received $329.75 in general payments during 2025 across 16 reported records.
AstraZeneca Pharmaceuticals LP accounted for 36.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $120.04 | 36.4% | 6 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $119.26 | 36.2% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.30 | 12.8% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $32.66 | 9.9% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.49 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.75 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $119.26 | 5 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $119.26 | 5 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $119.26 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $106.10 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.30 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.49 | 1 | 2025 |
Source payment records
|
|||||
| M-M-R II Normalized: m m r ii |
Biological | Merck Sharp & Dohme LLC | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.94 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 47 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
47 | 46 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 390 | 103 |
| Atorvastatin Calcium | Atorvastatin Calcium | 330 | 101 |
| Lisinopril | Lisinopril | 280 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 239 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 53 |
| Simvastatin | Simvastatin | 181 | 54 |
| Losartan Potassium | Losartan Potassium | 116 | 31 |
| Pantoprazole Sodium | Pantoprazole Sodium | 116 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 34 |
| Ezetimibe | Ezetimibe | 109 | 35 |
| Omeprazole | Omeprazole | 107 | 30 |
| Metformin Hcl | Metformin Hcl | 104 | 26 |
| Potassium Chloride | Potassium Chloride | 100 | 25 |
| Liothyronine Sodium | Liothyronine Sodium | 95 | 26 |
| Gabapentin | Gabapentin | 89 | 26 |
| Tramadol Hcl | Tramadol Hcl | 89 | 21 |
| Trazodone Hcl | Trazodone Hcl | 88 | 28 |
| Synthroid | Levothyroxine Sodium | 82 | 20 |
| Allopurinol | Allopurinol | 78 | 22 |
| Metformin Hcl Er | Metformin Hcl | 71 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 71 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 63 | 18 |
| Eliquis | Apixaban | 61 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 60 | 16 |
| Azithromycin | Azithromycin | 58 | 35 |
| Finasteride | Finasteride | 58 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 22 |
| Alprazolam | Alprazolam | 56 | 12 |
| Sertraline Hcl | Sertraline Hcl | 53 | 17 |
| Donepezil Hcl | Donepezil Hcl | 52 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 51 | 13 |
| Montelukast Sodium | Montelukast Sodium | 51 | 18 |
| Fenofibrate | Fenofibrate | 48 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 47 | 46 |
| Carvedilol | Carvedilol | 45 | 15 |
| Lorazepam | Lorazepam | 45 | 14 |
| Diazepam | Diazepam | 43 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 43 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 38 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 16 |
| Furosemide | Furosemide | 38 | 14 |
| Buspirone Hcl | Buspirone Hcl | 37 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 24 |
| Estradiol | Estradiol | 36 | 12 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 36 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 35 | 20 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 34 | 34 |
| Pregabalin | Pregabalin | 34 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 26 | 16 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Ibuprofen | Ibuprofen | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Spironolactone | Spironolactone | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Clonazepam | Clonazepam | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.75 · 16 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, BREZTRI, CAPVAXIVE, COMIRNATY, EVENITY, FARXIGA, GARDASIL 9, LAGEVRIO, M-M-R II, MOUNJARO, PREVNAR 20, PROLIA, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error